Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Free Cash Flow (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Free Cash Flow data on record, last reported at -$13.2 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 47.18% year-over-year to -$13.2 million; the TTM value through Dec 2025 reached -$47.2 million, down 133.83%, while the annual FY2025 figure was -$47.2 million, 133.83% down from the prior year.
  • Free Cash Flow reached -$13.2 million in Q4 2025 per ACRS's latest filing, down from -$11.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $22.0 million in Q3 2024 and bottomed at -$26.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$13.3 million, with a median of -$12.7 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 209.29% in 2023, then skyrocketed 189.28% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$17.1 million in 2021, then dropped by 8.94% to -$18.6 million in 2022, then soared by 61.36% to -$7.2 million in 2023, then decreased by 24.1% to -$8.9 million in 2024, then plummeted by 47.18% to -$13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$13.2 million in Q4 2025, -$11.0 million in Q3 2025, and -$10.0 million in Q2 2025.